Shoulder Innovations (SI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 26, 2026, with shareholders able to vote electronically or by phone using a control number.
Shareholders are asked to vote on the election of two Class I directors and the ratification of Deloitte & Touche LLP as the independent auditor for 2026.
The company is classified as an emerging growth company and follows reduced public company reporting requirements.
Forward-looking statements are included, subject to risks detailed in the annual report and SEC filings.
Voting matters and shareholder proposals
Proposal 1: Election of Robert Ball and Andrew Hykes as Class I directors for a three-year term.
Proposal 2: Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.
Board recommends voting FOR both proposals.
Shareholders may submit proposals for the 2027 meeting between December 30, 2026, and March 28, 2027, depending on meeting date.
Board of directors and corporate governance
Board consists of seven members post-meeting, with a staggered three-class structure.
Majority of directors are independent per NYSE rules; CEO and COO are not independent.
Board committees (Audit, Compensation, Nominating and Corporate Governance) are fully independent.
Lead Independent Director role established to enhance board accountability.
Corporate Governance Guidelines and Code of Ethics are in place and overseen by the Audit Committee.
Latest events from Shoulder Innovations
- Innovative implants, AI planning, and outpatient focus drive rapid growth and market leadership.SI
Canaccord Genuity's 46th Annual Growth Conference - Registering $300M in securities and 8.1M shares for resale, targeting ASC-driven growth.SI
Registration filing - Q2 revenue up 56% YoY, guidance raised, and implant sales and innovation drive growth.SI
Q2 2026 - Director elections and auditor ratification approved; no stockholder questions submitted.SI
AGM 2026 - Innovative implants and AI-driven planning fuel rapid growth in the $2.8B shoulder arthroplasty market.SI
Investor presentation - Q1 2026 revenue surged 65% to $16.7M, with margin gains and a raised full-year outlook.SI
Q1 2026 - Vote on director elections and auditor ratification at the June 26, 2026 annual meeting.SI
Proxy filing - Q4 revenue up 65% year-over-year; 2026 guidance targets 31–37% growth with strong margins.SI
Q4 2025 - Strong Q2 growth and innovative, efficient solutions drive momentum in the shoulder arthroplasty market.SI
Morgan Stanley 23rd Annual Global Healthcare Conference